Organic Active Ingredients TRIZ Cases

This case uses HCK inhibitor RK-20449 to improve lung function and survival while reducing inflammatory and fibrosis markers in IPF mice.

This case combines ginkgetin with remdesivir to reduce toxicity and increase efficacy in viral infection treatment.

Circulating plasma cell gene expression supports disease detection, monitoring, and therapy response prediction from whole blood.

This case examines fused bicyclic compounds balancing orexin-2 receptor activity, brain permeability, pharmacokinetics, and safety.

This case uses pyrazinamide derivatives to engage three ProRS pockets, enabling dual-stage parasite activity and host selectivity.

This case uses lithium and extended-release formulations to reduce PVCs while sustaining therapeutic serum concentrations over time.

A cannabinoid composition tuned to 20-35 mN/m forms sub-6 μm ultrasonic droplets for targeted deep-lung delivery.

A Gd-IgA1 binder linked to an ASGPR ligand routes circulating antibodies into hepatocytes for selective degradation.

This case uses liver-targeting siRNA to downregulate GPAM, reduce lipid accumulation, and address NAFLD and NASH.

This case uses EC3-selective CDH6 antibodies and a cytotoxic payload to improve internalization and tumor-directed delivery.

This case uses alcohol, polysorbate 80, and castor oil to solubilize fulvestrant without non-aqueous ester solvents.

Defined chemical series activate GCase, offering a potential lower-cost approach for Gaucher and Parkinson’s disease treatment.

This case shows how an antioxidant captures free radicals to protect an antifibrotic compound during formulation and storage.

A lyophilized solid separates storage from administration, enabling rapid reconstitution and ultra-low-dose intraarticular knee treatment.

Nanoparticle-delivered dsDNA stimulates innate immunity, supporting vaccines and infectious disease treatment in one formulation.

Small-molecule AIF inhibitors block apoptosis signaling to help preserve mitochondria and mitigate lung injury.

This case uses micronization, acidic buffering, and thixotropic agents to improve rilpivirine suspension uniformity, stability, and dosing.

3D printing and electrospinning create layered artificial bile ducts with UDCA for cholangiocyte differentiation and bile stone prevention.

Multiple sepiapterin crystal forms use X-ray fingerprints to support stability and therapeutic BH4 conversion.

Fusion granulation combines etoricoxib and tramadol to preserve stability, dissolution, bioavailability, and synergistic pain relief.

Uniaxially-aligned scaffolds deliver FTY720 to guide pro-regenerative immune cells, reduce inflammation, and support oral wound closure.

A crystalline S-oxprenolol dihydrogenphosphate salt raises melting point and supports stable solid oral formulations.

The case pairs levetiracetam-class drugs with GABAA α5 agonists for early intervention and sustained exposure in at-risk subjects.

β-Cyclodextrin solubilizes bilastine for parenteral delivery, combining rapid onset with up to 24-hour effectiveness.

Chiral sulfonate ester induction enables scalable, high-purity pyrimidine synthesis.

This case uses modified ANGPTL3 RNAi agents to suppress gene expression, reduce major lipids, and support infrequent dosing.

Probiotics and enzymes convert olive polyphenol precursors into HVA in vivo, supporting bone formation and cartilage health.

This case pairs a ginsenoside-derived tetracyclic triterpene with lenalidomide or thalidomide for selective, synergistic myeloma treatment.

This case combines attenuated Salmonella with drug-loaded liposomes to improve tumor accumulation and treatment of resistant cancers.

This case uses guanidinium and imidazole groups on a tranexamic scaffold to inhibit cancer viability and viral replication.

Specific amino lipid structures and composite formulations improve therapeutic delivery while reducing immunogenicity and toxicity.

Indole compounds directly inhibit dengue replication across four serotypes, combining broad coverage with improved chiral stability and pharmacokinetics.

This case combines two cartridges and independently controlled heaters to vaporize different substances simultaneously in one device.

Penetration enhancers, antioxidants, and gelling agents support stable ruboxistaurin delivery for hyperpigmentation treatment.

This case shows how intramuscular spermidine shifts muscle protein balance, suppressing degradation and promoting regeneration.

This synthesis uses base-catalyzed hydrolysis in water to limit methyl ester reformation and reduce false positives in cancer detection.

MSC-derived exosomes and pH buffers target GSM dryness and lubrication without estrogen.

This case converts enavogliflozin into an M1 metabolite that addresses selective SGLT2 limits through dual SGLT1/SGLT2 inhibition.

Spray- or freeze-dried crystalline powders combine alkaloid salts with sugar alcohols for stable inhalation delivery.

This injectable HA composition combines crosslinked hyaluronic acid with PN or PDRN for stronger rheology and enzyme resistance.

This case addresses cardiac toxicity and infusion efficiency with dosing regimens and stable Pertuzumab–Trastuzumab IV bag mixtures.

This case develops heavy- and light-chain CDR sequences that bind SARS-CoV-2 spike protein and neutralize Omicron variants.

This case combines azvudine with an EGFR/TKI inhibitor to improve tumor inhibition and delay resistance in non-small cell lung cancer.

This case links alkyl or perfluoroalkyl groups to nucleic acids for reagent-free siRNA delivery with low cytotoxicity.

Fluid bed granulation and rotary-wheel spray drying produce amorphous ipatasertib with better flow, density, and humidity stability.

This case uses a selective small-molecule MC1R agonist for oral dosing to delay phototoxicity, reduce pain events, and support daily life.

Separate cationic and anionic components enable stable, rapid nanoparticle preparation.

This case combines white vaseline with paraffin or beeswax to improve timolol absorption while limiting skin irritation.

A convergent synthesis route produces high-purity callyspongiolide analogs for clearer structural elucidation and biological study.

Tyr-Arg and Thr-Ser-Lys oligopeptides address incomplete calcium absorption by supporting osteoblast activity with minimal side effects.

Segmenting the dosage form into two layers prevents oxidative degradation of rosuvastatin and solubility issues with ezetimibe.

Replacing organic polymers with silica reduces dosage weight while maintaining moisture stability.

A lozenge combining silver salt with tobacco alkaloids to deliver nicotine while imparting an unfavorable taste to cigarette smoke.

Formula I compounds block cytokine production, replacing complex biologics with small molecules that improve safety and pharmacokinetics.

Combining piceatannol with gastrodin and cyclodextrins enhances solubility to treat microcirculation block induced by brain injury.

A Biota orientalis extract composition stimulates chondrocyte proliferation to promote cartilage growth.

Novel ionizable lipid nanoparticles enhance cellular uptake of therapeutic nucleic acids, resolving instability and low permeability barriers.

Buffer-free ketorolac and phenylephrine formulation eliminates adverse effects from traditional buffers while maintaining pH stability for three months.

Novel non-hormonal steroid compounds modulate NF-kB activity by inhibiting IκB kinases.

A topical composition combines flucytosine with penetration enhancers to treat skin infections.

Heterobifunctional molecules bridge mutant huntingtin protein and ubiquitin E3 ligase to drive targeted degradation of the disease-causing protein.

Segmented netrin-1 peptides enhance pathway activation efficiency and reduce infarct size by boosting nitric oxide levels.

Composite hydrogels with native skin components resolve the trade-off between extrudability and mechanical strength, enabling viable tissue regeneration.

Segmented phenylephrine particles with varied dissolution rates sustain therapeutic plasma levels, eliminating frequent dosing requirements.

Substituted pyrazinyl acrylic acids inhibit PASK kinase to regulate glycogen metabolism and suppress rapid protein synthesis in diabetes.

AAV9-mediated NEAT1 overexpression replaces invasive transplantation, reducing donor dependency and treatment costs.

A selenium-containing pharmaceutical composition reduces oxidative stress in cartilage cells to inhibit degeneration.

Modified molecular structures of amino chromen-2-one compounds overcome drug resistance in cancer and metabolic disorders.

GRM gene CNV biomarkers enable precise ASD diagnosis, guiding fasoracetam treatment to restore neurophysiology.

Two-step intravesical instillation of liposomal anesthetic and GAG-replenishing formulations treats bladder pain syndrome without systemic side effects.

Compound A targets mu-kappa opioid receptor heteromers to treat chronic and acute pain while reducing dependence and tolerance.

An impregnated resin ear tag releases a macrolide and synergist mixture to overcome pest resistance while reducing invasive administration.

SeroVital oral supplement replaces invasive injections by stimulating pituitary gland to release human growth hormone via specific amino acid blend.

A heterocyclic compound with a hydroxyethoxy group inhibits monoamine reuptake to provide sustained pharmacological action.

Replacing immunoglobulins with nucleic acid aptamers reduces synthesis cost and eliminates immunogenicity while maintaining high specificity for LAR protein.

Nested capsules use varying dissolution rates to target delivery of bioactive compounds, resolving poor user compliance caused by unpleasant postbiotic taste.

Combining cotinine with antioxidants restores GFAP+ cell numbers and morphology to treat stress-induced depression.

Combining LIV-1 ADCs with chemotherapy reduces tumor volumes while lowering toxic effects through synergistic action.

Measuring serum estriol levels and increasing dosage when below 6 ng/mL reduces cortical gray matter atrophy in multiple sclerosis.

S-adenosylmethionine salts stabilize at higher temperatures by combining strong inorganic acids with calcium or magnesium oxides to prevent degradation.

PCR-based plasma detection of piR-hsa-120522 replaces invasive bronchoscopy and radiation imaging with a molecular marker assay for early diagnosis.

Pyridazinone-based compound selectively inhibits DDR1 kinase activity, reducing off-target side effects like hypertension in fibrosis and cancer treatment.

Merges benzoate and phenylbutyrate to activate PPARγ, resolving insufficient anti-inflammatory efficacy of single-compound treatments.

A GABAA receptor modulator targets alpha2 and alpha3 subunits to deliver analgesia.

L-BAIBA mediates muscle-kidney signaling to lower serum phosphate while preventing myopathy side effects.

Conjugating Bcl inhibitors to dendrimers improves solubility and tolerability, addressing delivery challenges in cancer treatment.

Combining nitrogen-containing bisphosphonates with glucocorticoids to modulate endosomal pH and suppress inflammatory cytokines.

Combines sacituzumab govitecan with magrolimab to eliminate Trop-2 positive tumors while reducing systemic toxicity in triple negative breast cancer.

Acid treatment removes Boc groups from 2-AA-Boc to release active labeling agents, bypassing DEA restrictions on controlled substances.

A medium molecular weight heparin fraction with narrow distribution decouples anticoagulant action from bleeding potential.

Geranylated flavonoids from Paulownia tomentosa inhibit neuraminidase activity, addressing low bioavailability and side effects of conventional antiviral drugs.

Replacing peanut oil with Gelucire 44/14 and ultra-micronized particles reduces pharmacokinetic variability in progesterone absorption.

Novel piperidine derivatives act as GPR119 agonists to enhance glucose-dependent insulin secretion while reducing adverse effects like hypoglycemia.

A fused ring compound inhibits FGFR and VEGFR kinases to treat tumors at lower doses.

A hairpin nucleic acid molecule with a double-stranded section under 19 base pairs induces type I interferon production.

Fibrin matrix forms around active agent composition on vessel wall to maintain lesion patency for six months.

Covalent Btk inhibitors suppress NF-kB activation to reduce tumor growth in ABC-DLBCL patients with CD79B mutations.